Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: A meta-analysis of double-blind, randomized, placebo-controlled trials

International Journal of Neuropsychopharmacology

Volumn 16, Issue 3, 2013, Pages 557-574

  Dold, Markus ^a   Aigner, Martin ^a   Lanzenberger, Rupert ^a   Kasper, Siegfried ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antipsychotics; meta analysis; obsessive compulsive disorder; serotonin reuptake inhibitors; treatment resistance

Indexed keywords

ARIPIPRAZOLE; CLOMIPRAMINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADD ON THERAPY; ARTICLE; COMPARATIVE STUDY; DIZZINESS; DROWSINESS; DRUG EFFICACY; DYSPEPSIA; FATIGUE; HEADACHE; HUMAN; INCREASED APPETITE; INSOMNIA; IRRITABILITY; META ANALYSIS; MONOTHERAPY; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESSNESS; RIGIDITY; RISK FACTOR; SEDATION; SIDE EFFECT; SOMNOLENCE; THERAPY EFFECT; TINNITUS; TREATMENT OUTCOME; TREATMENT RESISTANT OBSESSIVE COMPULSIVE DISORDER; TREATMENT RESPONSE; VERTIGO; WEIGHT GAIN; XEROSTOMIA; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84874638738     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712000740     Document Type: Article

References (63)

1. APA 2007 American Psychiatric Association : Practice Guideline for the Treatment of Patients with Obsessive-Compulsive Disorder. Arlington, VA American Psychiatric Association.
2. Baldwin DS, Waldman S, Allgulander C (2011). Evidencebased pharmacological treatment of generalized anxiety disorder. International Journal of Neuropsychopharmacology 14, 697-710.
3. Bandelow B (2008). The medical treatment of obsessivecompulsive disorder and anxiety. CNS Spectrums 13 (Suppl. 14), 37-46.
4. Bandelow B, Zohar J, Hollander E, Kasper S, et al. (2008). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision. World Journal of Biological Psychiatry 9, 248-312.
5. Batelaan NM, van Balkom AJ, Stein DJ (2012). Evidencebased pharmacotherapy of panic disorder : an update. International Journal of Neuropsychopharmacology 15, 403-415.
6. Berlin HA, Koran LM, Jenike MA, Shapira NA, et al. (2011). Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. Journal of Clinical Psychiatry 72, 716-721.
7. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, et al. (2006). A systematic review: antipsychotic augmentation with treatment refractory obsessivecompulsive disorder. Molecular Psychiatry 11, 622-632. (Pubitemid 43989810)
8. Bloch M, State M, Pittenger C (2011). Recent advances in Tourette syndrome. Current Opinion in Neurology 24, 119-125.
9. Borenstein M, Hedges LV, Higgins JPT, Rothstein H (2006). Comprehensive Meta-Analysis, Version 2. Englewood, NY: Biostat.
10. Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, et al. (2004). Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: A placebo-controlled trial. Journal of Clinical Psychiatry 65, 565-568.
11. Carey PD, Vythilingum B, Seedat S, Muller JE, et al. (2005). Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder : A double-blind, randomised, placebo-controlled study. BMC Psychiatry 5, 5.
12. Cohen J (1969). Statistical Power analysis for the Behavioural Sciences. New York: Academic Press.
13. Coric V, Taskiran S, Pittenger C, Wasylink S, et al. (2005). Riluzole augmentation in treatment-resistant obsessivecompulsive disorder : an open-label trial. Biological Psychiatry 58, 424-428. (Pubitemid 41219711)
14. Cottraux J, Bouvard MA, Milliery M (2005). Combining pharmacotherapy with cognitive-behavioural interventions for obsessive-compulsive disorder. Cognitive Behaviour Therapy 34, 185-192. (Pubitemid 41358485)
15. Denys D, Fineberg N, Carey PD, Stein DJ (2007). Quetiapine addition in obsessive-compulsive disorder : is treatment outcome affected by type and dose of serotonin reuptake inhibitors? Biological Psychiatry 61, 412-414. (Pubitemid 46108696)
16. Denys D, de Geus F, van Megen HJ, Westenberg HG (2004c). A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessivecompulsive disorder refractory to serotonin reuptake inhibitors. Journal of Clinical Psychiatry 65, 1040-1048.
17. Denys D, van Megen HJ, van der Wee N, Westenberg HG (2004a). A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. Journal of Clinical Psychiatry 65, 37-43.
18. Denys D, Zohar J, Westenberg HG (2004b). The role of dopamine in obsessive-compulsive disorder : preclinical and clinical evidence. Journal of Clinical Psychiatry 65 (Suppl. 14), 11-17.
19. Der-Simonian R, Laird N (1986). Meta-analysis in clinical trials. Controlled Clinical Trials 7, 177-188. (Pubitemid 17189972)
20. Diniz JB, Shavitt RG, Fossaluza V, Koran L, et al. (2011). A double-blind randomized controlled trial of fluoxetine plus quetiapine or clomipramine vs. fluoxetine plus placebo for obsessive-compulsive disorder. Journal of Clinical Psychopharmacology 31, 763-768.
21. Dold M, Aigner M, Lanzenberger R, Kasper S (2011). Effektivitä t einer Augmentationstherapie mit Antipsychotika bei therapieresistenten Zwangsstörungen-eine Metaanalyse doppelblinder, randomisierter, placebokontrollierter Studien [in German]. Fortschritte der Neurologie Psychiatrie 79, 453-466.
22. Dupuy JM, Ostacher MJ, Huffman J, Perlis RH, Nierenberg AA (2011). A critical review of pharmacotherapy for major depressive disorder. International Journal of Neuropsychopharmacology 14, 1417-1431.
23. Eddy KT, Dutra L, Bradley R, Westen D (2004). A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clinical Psychology Review 24, 1011-1030. (Pubitemid 40247306)
24. Egger M, Davey SG, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 315, 629-634. (Pubitemid 27387172)
25. Erzegovesi S, Guglielimo E, Siliprandi F, Bellodi L (2005). Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder : A double-blind, placebo-controlled study. European Neuropsychopharmacology 15, 69-74. (Pubitemid 39574401)
26. Falkai P, Wobrock T, Lieberman J, Glenthoj B, et al. (2006). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World Journal of Biological Psychiatry 7, 5-40. (Pubitemid 43878525)
27. Fineberg NA, Brown A, Reghunandanan S, Pampaloni I (2012). Evidence-based pharmacotherapy of obsessivecompulsive disorder. International Journal of Neuropsychopharmacology. Published online : 9 January 2012. doi :10.1017/S1461145711001829.
28. Fineberg NA, Sivakumaran T, Roberts A, Gale T (2005). Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder : A randomized controlled treatment study. International Clinical Psychopharmacology 20, 223-226. (Pubitemid 40896377)
29. Fineberg NA, Tonnoir B, Lemming O, Stein DJ (2007). Escitalopram prevents relapse of obsessive-compulsive disorder. European Neuropsychopharmacology 17, 430-439. (Pubitemid 46497661)
30. Fornaro M (2011). Switching from serotonin reuptake inhibitors to agomelatine in patients with refractory obsessive-compulsive disorder : A 3 month follow-up case series. Annals of General Psychiatry 10, 5.
31. Goddard AW, Shekhar A, Whiteman AF, McDougle CJ (2008). Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder. Drug Discovery Today 13, 325-332.
32. Goodman WK, Price LH, Rasmussen SA, Mazure C, et al. (1989). Yale-Brown Obsessive-Compulsive Scale I. Development, use, and reliability. Archives of General Psychiatry 46, 1006-1011.
33. Higgins JPT, Green S (2011). Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.1 [updated online March 2011]. Chichester: John Wiley & Sons.
34. Hollander E, Rossi NB, Sood E, Pallanti S (2003). Risperidone augmentation in treatment-resistant obsessive-compulsive disorder : A double-blind, placebo-controlled study. International Journal of Neuropsychopharmacology 6, 397-401. (Pubitemid 38146258)
35. Huf W, Kalcher K, Pail G, Friedrich ME, et al. (2011). Meta-analysis : fact or fiction? How to interpret meta-analyses. World Journal of Biological Psychiatry 12, 188-200.
36. Komossa K, Depping AM, Meyer M, Kissling W, Leucht S (2010). Second-generation antipsychotics for obsessive compulsive disorder. Cochrane Database of Systematic Reviews 8, CD008141.
37. Kordon A, Wahl K, Koch N, Zurowski B, et al. (2008). Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder : A double-blind, randomized, placebo-controlled study. Journal of Clinical Psychopharmacology 28, 550-554.
38. Li X, May RS, Tolbert LC, Jackson WT, et al. (2005). Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder : A crossover study. Journal of Clinical Psychiatry 66, 736-743. (Pubitemid 40942420)
39. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH (2000). A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Archives of General Psychiatry 57, 794-801. (Pubitemid 30650116)
40. McDougle CJ, Goodman WK, Leckman JF, Lee NC, et al. (1994). Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. Archives of General Psychiatry 51, 302-308.
41. Maina G, Pessina E, Albert U, Bogetto F (2008). 8-week, single-blind, randomized trial comparing risperidone vs. olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. European Neuropsychopharmacology 18, 364-372.
42. Matsunaga H, Nagata T, Hayashida K, Ohya K, et al. (2009). A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. Journal of Clinical Psychiatry 70, 863-868.
43. Metin O, Yazici K, Tot S, Yazici AE (2003). Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder : an open trial. Human Psychopharmacology 18, 463-467. (Pubitemid 37038343)
44. Mowla A, Khajeian AM, Sahraian A, Chohedri AH, Kashkoli F (2010). Topiramate augmentation in resistant OCD: A double-blind placebo-controlled clinical trial. CNS Spectrums 15(11). Published online.
45. Muscatello MR, Bruno A, Pandolfo G, Micò U, et al. (2011). Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder : A double-blind, placebocontrolled study. Journal of Clinical Psychopharmacology 31, 174-179.
46. National Institute for Clinical Excellence (2006). Obsessive Compulsive Disorder : Core Interventions in the Treatment of Obsessive Compulsive Disorder and Body Dysmorphic Disorder. London: National Institute for Clinical Excellence.
47. Ninan PT, Koran LM, Kiev A, Davidson JR (2006). Highdose sertraline strategy for non-responders to acute treatment for obsessive-compulsive disorder : A multicentre double-blind trial. Journal of Clinical Psychiatry 67, 15-22. (Pubitemid 43213277)
48. Orwin RG (1983). A fail-safe N for effect-size in metaanalysis. Journal of Statistics Education 8, 157-159.
49. Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E (2009). Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder : A preliminary, single-blind, prospective study. CNS Drugs 23, 1047-1055.
50. Pallanti S, Quercioli L (2006). Treatment-refractory obsessive-compulsive disorder : methodological issues, operational definitions and therapeutic lines. Progress in Neuro-Psychopharmacology and Biological Psychiatry 30, 400-412.
51. Pallanti S, Quercioli L, Koran LM (2002). Citalopram intravenous infusion in resistant obsessive-compulsive disorder : an open trial. Journal of Clinical Psychiatry 63, 796-801.
52. Pittenger C, Kelmendi B, Wasylink S, Bloch MH, Coric V (2008). Riluzole augmentation in treatment-refractory obsessive compulsive disorder : A series of 13 cases, with long-term follow-up. Journal of Clinical Psychopharmacology 28, 363-367.
53. Selvi Y, Atli A, Aydin A, Besiroglu L, et al. (2011). The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitorrefractory obsessive-compulsive disorder : A single-blind, randomised study. Human Psychopharmacology 26, 51-57.
54. Shapira NA, Ward HE, Mandoki M, Murphy TK, et al. (2004). A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessivecompulsive disorder. Biological Psychiatry 55, 553-555. (Pubitemid 38338545)
55. Skapinakis P, Papatheodorou T, Mavreas V (2007). Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessivecompulsive disorder : A meta-analysis of the randomized controlled trials. European Neuropsychopharmacology 17, 79-93. (Pubitemid 44779187)
56. Soltani F, Sayyah M, Feizy F, Malayeri A (2010). A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. Human Psychopharmacology 25, 509-513.
57. Soomro GM, Altman D, Rajagopal S, Oakley-Browne M (2008). Selective serotonin re-uptake inhibitors (SSRIs) vs. placebo for obsessive compulsive disorder (OCD). Cochrane Database of Systematic Reviews 23, CD001765.
58. Stein DJ, Andersen EW, Tonnoir B, Fineberg N (2007). Escitalopram in obsessive-compulsive disorder : A randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Current Medical Research and Opinion 23, 701-711. (Pubitemid 46631473)
59. Stewart SE, Jenike EA, Hezel DM, Stack DE, et al. (2010). A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. Journal of Clinical Psychopharmacology 30, 34-39.
60. The Cochrance Collaboration (2011). Software Review Manager (RevMan), Version 5.1.4. Oxford: The Cochrance Collaboration.
61. Vulink NC, Denys D, Fluitman SB, Meinardi JC, Westenberg HG (2009). Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder : A randomized, double-blind, placebo-controlled study of 76 patients. Journal of Clinical Psychiatry 70, 1001-1008.
62. Vulink NC, Figee M, Denys D (2011). Review of atypical antipsychotics in anxiety. European Neuropsychopharmacology 21, 429-449.
63. Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL (1987). Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. Archives of General Psychiatry 44, 946-951.